blister packets

Centene Corp. agreed to divest two pharmacy businesses for about $2.8 billion, in line with the health insurer’s strategy to exit the pharmacy benefit management space.

U.S. regulators on June 7 approved Biogen Inc.’s aducanumab as the first treatment to attack a likely cause of Alzheimer’s disease despite controversy over whether the clinical evidence proves the drug works, sending the company’s shares soaring.

Novartis’s heart failure drug Entresto will be subjected to a battery of new trials as the Swiss drugmaker seeks to boost the medicine after a disappointing introduction.

Cigna signed deals that will pay the makers of Repatha and Praluent based on how well their customers respond to them.

News that Novartis’s heart drug Entresto cuts the risk of re-hospitalization might have helped Chief Executive Joe Jimenez realize his ambition of getting insurers to pay more for treatments when they cut overall medical costs. Instead Jimenez and Severin Schwan, CEO of cross-town rival Roche, have been forced to concede that insurance companies, especially in […]

U.S. health officials said they expect 10 million people to be enrolled in healthcare plans through state-based insurance exchanges by the end of 2016, with more than one-quarter of eligible uninsured Americans signing up during this fall’s open enrolment period.   In estimates released on Thursday, the U.S. Department of Health and Human Services forecast […]

As U.S. health insurers chart an unprecedented consolidation of the industry, hospitals are taking a fresh look at becoming insurers themselves to keep more of their patients’ healthcare dollars in house.   Among the country’s largest insurers, Aetna Inc struck a deal to buy Humana Inc, while Anthem Inc agreed to acquire Cigna Corp. Both […]

U.S. oncologists, aware that patients are paying more of the costs of expensive cancer drugs, are increasingly declining to prescribe medicines that have scant or no effect, even as a last resort. At least half a dozen drugs, including colon cancer treatments Cyramza, from Eli Lilly & Co, and Stivarga, sold by Bayer AG, aren’t […]

NEW YORK – A New York Times article excoriated Valeant Pharmaceuticals International, Inc. (VRX) for the amount the company spends on research and development versus the amount it spends on mergers and acquisitions after the Quebec-based company quadrupled the price on a 55-year-old drug that treats Wilson Disease, a genetic disorder.   The Times highlights […]

The U.S. Food and Drug Administration on Friday approved Merck & Co Inc’s immunotherapy, Keytruda, for patients with the most common form of lung cancer whose tumors produce a specific biological marker. The FDA approval for Keytruda in advanced non-small cell lung cancer is for patients whose tumors express PD-L1, a protein targeted by the […]